News – CMS

2026-07-27

CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Finjuve, animproved new drug, is the first and only topical finasteride product worldwide approved for the treatment of androgenetic alopecia. Its efficacy is comparable to oral finasteride, while showing 100-fold lower systemic exposure and less impact on serum DHT levels compared with oral finasteride, offering an effective hair-loss treatment option with lower risk. Ciclopoli, a branded drug, uses patented HPCH water-soluble transungual technology. It does not require nail filing or organic solvents to remove the film, combining strong efficacy, safety, and convenience, and offering a superior topical treatment option for onychomycosis patients. Leveraging itsestablished registration and commercialization capabilities across Southeast Asia, Rxilient will accelerate the launch of both products, injecting new momentum into business growth in the region. Recently, the Southeast Asia business subsidiary of China Medical System (“CMS”), Rxilient Medical Pte. Ltd. (“Rxilient”), entered into a partnership with Polichem S.A., a subsidiary of Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology. Rxilient obtained […]

Learn More

2026-07-17

Dual ESG Recognition: CMS Named Among “China ESG Leaders 2026” and Honored with the “Green Supply Chain Leadership Award”

Recently, SynTao Green Finance officially released the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026. China Medical System Holdings Limited (“CMS” or “the Group”) was successfully named among “China ESG Leaders 2026”, recognized for its long-term dedication and outstanding practices in the Environmental, Social, and Governance (ESG) fields. Additionally, CMS was honored with the “Green Supply Chain Leadership Award” in the ESG selection hosted by Stockstar. This double recognition underscores the strong affirmation from professional institutions and the market for the Group’s sustainable development initiatives. Published by SynTao Green Finance, a leading ESG rating agency in China, the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026 is widely recognized for its high credibility and influence. Stockstar’s “ESG New Benchmark Awards”, themed “Innovation, Co-governance, Long-term Value”, introduced the “Green Supply Chain Leadership Award” for the first time. The award specifically focuses on corporate practices and achievements in building green, low-carbon, and responsible supply chains. As […]

Learn More

2026-07-15

China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). Through administered orally, targeting and inhibiting complement factor B,it blocks abnormal activation of the alternative complement pathway, and thereby slows the progression of complement dysregulation-related diseases such as age-related macular degeneration (“AMD”), offering a potentially superior and more convenient treatment option[1]. CMS-D017 has demonstrated favourable efficacy and safety profiles in preclinical studies. Upon approval for marketing, CMS-D017 will synergise with the marketed innovative drug Beovu®(diabetic macular oedema, etc.), the branded drug Lucentis® (neovascular age-related macular degeneration, etc.), and the exclusive drug Augentropfen Stulln Mono Eye Drops (senile macular degeneration and all forms of asthenopia), building a multi-layered, precise and comprehensive solution for ophthalmic diseases. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 15 July 2026, the Group’s self-developed innovative drug, Complement Factor B inhibitor CMS-D017 capsules (“CMS-D017” or the “Product”), obtained the Drug Clinical Trial Approval Notice […]

Learn More

Company News

Latest News

CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Dual ESG Recognition: CMS Named Among “China ESG Leaders 2026” and Honored with the “Green Supply Chain Leadership Award”

China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

All News